Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI110524

Inactivation of Factor XIa by Plasma Protease Inhibitors: PREDOMINANT ROLE OF α1-PROTEASE INHIBITOR AND PROTECTIVE EFFECT OF HIGH MOLECULAR WEIGHT KININOGEN

Cheryl F. Scott, Marc Schapira, Harold L. James, Allen B. Cohen, and Robert W. Colman

Thrombosis Research Center, Philadelphia, Pennsylvania 19140

Hematology-Oncology and Pulmonary Sections of the Department of Medicine, Temple University Health Sciences Center, Philadelphia, Pennsylvania 19140

Find articles by Scott, C. in: PubMed | Google Scholar

Thrombosis Research Center, Philadelphia, Pennsylvania 19140

Hematology-Oncology and Pulmonary Sections of the Department of Medicine, Temple University Health Sciences Center, Philadelphia, Pennsylvania 19140

Find articles by Schapira, M. in: PubMed | Google Scholar

Thrombosis Research Center, Philadelphia, Pennsylvania 19140

Hematology-Oncology and Pulmonary Sections of the Department of Medicine, Temple University Health Sciences Center, Philadelphia, Pennsylvania 19140

Find articles by James, H. in: PubMed | Google Scholar

Thrombosis Research Center, Philadelphia, Pennsylvania 19140

Hematology-Oncology and Pulmonary Sections of the Department of Medicine, Temple University Health Sciences Center, Philadelphia, Pennsylvania 19140

Find articles by Cohen, A. in: PubMed | Google Scholar

Thrombosis Research Center, Philadelphia, Pennsylvania 19140

Hematology-Oncology and Pulmonary Sections of the Department of Medicine, Temple University Health Sciences Center, Philadelphia, Pennsylvania 19140

Find articles by Colman, R. in: PubMed | Google Scholar

Published April 1, 1982 - More info

Published in Volume 69, Issue 4 on April 1, 1982
J Clin Invest. 1982;69(4):844–852. https://doi.org/10.1172/JCI110524.
© 1982 The American Society for Clinical Investigation
Published April 1, 1982 - Version history
View PDF
Abstract

Factor XIa is a plasma protease that, by activating Factor IX, plays an important role in the early phase of the intrinsic pathway of blood coagulation. Four plasma protease inhibitors, α1-protease inhibitor, antithrombin III, C1-inhibitor, and α2-plasmin inhibitor, have been reported to inactivate human Factor XIa, but their quantitative contribution to the inactivation of Factor XIa in plasma has not been fully assessed. Using purified systems, we observed that the second-order rate constants for the reaction of Factor XIa with α1-protease inhibitor, antithrombin III, and CI-inhibitor were 4.08, 10, and 14.6 M−1 min−1 × 103, respectively. The pseudo-first-order rate constants, at plasma concentration of the inhibitors, were 1.86 × 10−1, 4.68 × 10−2, and 2.4 × 10−2 min−1, respectively. These kinetic data predict that α1-protease inhibitor should account for 68%, antithrombin III for 16%, and C1-inhibitor and the equipotent α2-plasmin inhibitor each for 8% of the total inhibitory activity of plasma against Factor XIa. The rate of inactivation of Factor XIa in various plasma samples specifically deficient in inhibitors was consistent with these predictions.

Factor XI, the zymogen form of Factor XIa, circulates in plasma associated with the contact system cofactor, high molecular weight kininogen (HMW kininogen). Kinetic analysis indicated the existence of a reversible bimolecular Factor XIa-HMW kininogen complex with a dissociation constant (Kd) = 0.17 μM. The light chain derived from HMW kininogen decreased the inactivation rate of Factor XIa by C1-inhibitor with a Kd of 0.08 μM for a complex of Factor XIa and the light chain derived from HMW kininogen. The protective effect of HMW kininogen was confirmed by the finding that the inactivation rate of Factor XIa in kininogen-deficient plasma was increased over normal plasma.

The present study confirms that α1-protease inhibitor is the major inhibitor of Factor XIa in plasma, and that the formation of a reversible complex between Factor XIa and HMW kininogen decreases the rate of inactivation of the enzyme by its inhibitors.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 844
page 844
icon of scanned page 845
page 845
icon of scanned page 846
page 846
icon of scanned page 847
page 847
icon of scanned page 848
page 848
icon of scanned page 849
page 849
icon of scanned page 850
page 850
icon of scanned page 851
page 851
icon of scanned page 852
page 852
Version history
  • Version 1 (April 1, 1982): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts